NCIC CLINICAL TRIALS GROUP

INVESTIGATIONAL NEW DRUG COMMITTEE

DISEASE SITE COMMITTEE MEETING
FINAL OPEN AGENDA

Friday, May 1, 2009 ~ 13.30 – 16.30
Room: Mountbatten Salon

Chair: Hal Hirte

1.30 p.m. Welcome from the chair

FINAL TRIAL REPORTS

IND.165: Rand. Phase II Docetaxel +/- OGX011 in prostate cancer Dr. K. Chi
IND.172: Phase II Bortezomib + gemcitabine Mantle Cell Lymphoma Dr. T. Kouroukis
IND.185: Phase II Sunitinib Ovarian Cancer Dr. J. Biagi
IND.182: Phase II Sunitinib DLBCL Dr. R. Buckstein
IND.173: Phase I/II AZD0530 + Gemcitabine Pancreas Dr. M. Moore

2:30 p.m. SCIENTIFIC SESSION:
Molecular Endpoints and Opportunities in Early Cancer Clinical Trials
Chairs: Janet Dancey and Hal Hirte

(20’) Molecular imaging: Canada’s potential to contribute to cancer drug development
Dr. Francois Bénard
BC Cancer Research Centre, Vancouver BC

(20’) ‘Living’ tumour banks and their potential for tumour-specific screening for activity
Dr. R. Bristow
Princess Margaret Hospital, Toronto ON

(20’) Circulating Tumour Cells: report of NCIC CTG-OICR workshop
Dr. P. Bradbury
Drug Development Fellow, NCIC CTG

3:30 p.m. Discussion

3:50 pm New / Planned Studies, Report from Closed IND meeting
Dr. E. Eisenhauer, Dr. L. Seymour

4:30 p.m. Adjourn